Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05645718
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 68
- Registration Number
- NCT05620862
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 300
- Registration Number
- NCT05605899
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 24
- Registration Number
- NCT05600686
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-10-05
- Target Recruit Count
- 60
- Registration Number
- NCT05594784
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 900
- Registration Number
- NCT05578976
- Locations
- 🇺🇸
Orlando Health Cancer Institute /ID# 232626, Orlando, Florida, United States
🇺🇸University of Illinois at Chicago /ID# 226889, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland, United States
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Conditions
- Interventions
- Procedure: Surgical resectionOther: Educational and Media InterventionOther: SOC, Educational and Media InterventionProcedure: Ommaya/VPSDrug: MethotrexateDrug: CisplatinDrug: VincristineDrug: CyclophosphamideDrug: CarboplatinDrug: TopotecanDrug: PegfilgrastimDrug: EtoposideDrug: FilgrastimRadiation: Irradiation
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05535166
- Locations
- 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05521087
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 26
- Registration Number
- NCT05504291
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.